PMID- 34963823
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 9
DP  - 2021
TI  - A retrospective study assessing the factors associated with visual outcome in 
      retinal vein occlusion patients after anti-VEGF therapy.
PG  - e12599
LID - 10.7717/peerj.12599 [doi]
LID - e12599
AB  - BACKGROUND: Retinal vein occlusion (RVO) is one of the most frequent retinal 
      vascular diseases. In this study, we aimed to investigate the predictive factors 
      of visual outcome for RVO patients who underwent anti-vascular endothelial growth 
      factor (VEGF) therapy. METHODS: RVO patients who underwent anti-VEGF treatment 
      were recruited in this study from January 2018 to June 2020. Clinical data and 
      optical coherence tomography (OCT) parameters were retrospectively reviewed. 
      Best-corrected visual acuity (BCVA) was examined at baseline and after anti-VEGF 
      therapy. Predictive factors associated with visual outcome were assessed by 
      logistic regression model. Treatment-related adverse events were also recorded. 
      RESULTS: The average logMAR BCVA was 0.91 at baseline and 0.70 at final 
      examination (P = 0.003). Among 75 patients, 41 experienced visual improvement 
      were categorized as group A, the remaining 34 patients without improved vision 
      were categorized as group B. Patients in group A demonstrated better visual 
      outcomes, including decreased logMAR BCVA (average logMAR BCVA: 0.53 in group A 
      vs. 0.91 in group B, P < 0.001) and central retinal thickness (CRT) (average CRT: 
      230.88 microm in group A vs. 404.97 microm in group B, P < 0.001) after anti-VEGF 
      treatment. Multivariable analysis showed that injection frequency (odds ratio 
      [OR], 2.623; 95% confidence interval [CI], [1.282-5.366]), hypertension (odds 
      ratio [OR], 0.189; 95% CI [0.044-0.811]), hyperlipemia (odds ratio [OR], 0.195; 
      95% CI [0.040-0.941]) and external limiting membrane (ELM) disruption (odds ratio 
      [OR], 0.148; 95% CI [0.032-0.691]) were all significantly associated with the 
      visual outcome of RVO patients who underwent anti-VEGF treatment. In general, 
      anti-VEGF therapy was feasible for all RVO patients, though the response to 
      anti-VEGF was suboptimal in certain patients. Prognostic factors including 
      injection frequency, hypertension, hyperlipemia and ELM disruption may all be 
      useful to provide predictive information of visual outcome of RVO patients in 
      response to anti-VEGF treatment.
CI  - (c)2021 Liu et al.
FAU - Liu, Xiaoran
AU  - Liu X
AD  - Medical College, Anhui University of Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
FAU - Xie, Chi
AU  - Xie C
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
FAU - Wang, Yun
AU  - Wang Y
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
FAU - Xu, Yue
AU  - Xu Y
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
FAU - Zhu, Shaojin
AU  - Zhu S
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
FAU - Fang, Yan
AU  - Fang Y
AD  - Department of Ophthalmology, the First Affiliated Hospital of Anhui University of 
      Science and Technology, Huainan, China.
AD  - Department of Ophthalmology, the First People's Hospital of Huainan, Huainan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20211206
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC8656372
OTO - NOTNLM
OT  - Anti-VEGF therapy
OT  - Predictive factors
OT  - Prognosis
OT  - Retinal vein occlusion
COIS- The authors declare there are no competing interests.
EDAT- 2021/12/30 06:00
MHDA- 2021/12/30 06:01
PMCR- 2021/12/06
CRDT- 2021/12/29 05:37
PHST- 2021/05/17 00:00 [received]
PHST- 2021/11/15 00:00 [accepted]
PHST- 2021/12/29 05:37 [entrez]
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2021/12/30 06:01 [medline]
PHST- 2021/12/06 00:00 [pmc-release]
AID - 12599 [pii]
AID - 10.7717/peerj.12599 [doi]
PST - epublish
SO  - PeerJ. 2021 Dec 6;9:e12599. doi: 10.7717/peerj.12599. eCollection 2021.